The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Screening for Lung Cancer in Current or Past Smokers With Chronic Obstructive Pulmonary Disease
Official Title: A Randomised Controlled Trial of Surveillance for the Early Detection of Lung Cancer in an at Risk Group [Lung-SEARCH Trial]
Study ID: NCT00512746
Brief Summary: RATIONALE: Screening tests or exams may help doctors find lung cancer sooner, when it may be easier to treat. PURPOSE: This randomized clinical trial is studying screening tests or exams to see how well they work compared to usual care in finding early stage lung cancer in current or past smokers with chronic obstructive pulmonary disease.
Detailed Description: OBJECTIVES: Primary * To show that the proportion of lung cancer diagnosed at stage I or II is significantly greater in the surveillance arm than in the control arm. Secondary * Establish whether sputum cytology and/or cytometry can be employed to stratify patients with chronic obstructive pulmonary disease (COPD) according to their risk of developing incidence lung cancer. * Identify patients with pre-invasive lesions in their airways and examine the risk of developing lung cancer in patients harboring these lesions. * Provide an opportunity to archive blood samples from patients under surveillance to enable the identification of markers of disease progression. * Examine the compliance of regular screening among patients in this high-risk group. * Determine the proportion of patients in which it is not possible to provide a sputum screening result. OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified according to recruiting site, age, gender, smoking history (current vs ex-smoker) and severity of chronic obstructive pulmonary disease (COPD) (mild vs moderate). Patients are randomized to 1 of 2 arms. * Control arm: Patients are managed according to the usual practice of their hospital or general practice for their COPD treatment. They undergo no particular investigations except those that may arise due to a change in their clinical condition. Those patients who are not diagnosed with lung cancer during the course of the study are offered a chest x-ray after 5 years of follow-up. * Surveillance arm: Patients undergo surveillance for 5 years. A sputum sample is collected for cytology and cytometry. If the sputum sample is normal the patient is asked to provide a sputum sample annually. If the sputum sample is abnormal the patient undergoes an annual spiral CT scan followed by autofluorescence bronchoscopy. At bronchoscopy, the following samples are taken: bronchial washings, bronchial brushings, and bronchial biopsies. Bronchoscopy is repeated every 4-12 months depending upon the histology results. If an invasive lesion is found, the patient is referred for treatment via the normal hospital systems. Any remaining sputum sample is stored frozen as part of the tissue bank associated with this trial. Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Papworth Hospital, Cambridge, England, United Kingdom
Walsgrave Hospital, Coventry, England, United Kingdom
Leeds General Infirmary, Leeds, England, United Kingdom
University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
Chelsea Westminster Hospital, London, England, United Kingdom
Royal Brompton Hospital, London, England, United Kingdom
University College Hospital - London, London, England, United Kingdom
Wythenshawe Hospital, Manchester, England, United Kingdom
Sunderland Royal Hospital, Sunderland, England, United Kingdom
Respiratory Research Office Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
Name: Stephen G. Spiro
Affiliation: University College London Hospitals
Role: STUDY_CHAIR